MET FISH
Use
This fluorescence in situ hybridization (FISH) test assesses MET gene copy number alterations—specifically amplification—via probes targeting MET (7q31) and centromere 7. It is intended to detect MET amplification in multiple solid tumor cancers (including non‑small cell lung cancer, gastric, esophageal, and endometrial cancers), providing diagnostic and potentially prognostic information. MET amplification may indicate genomic aberrations driving tumor growth or therapy resistance.
Special Instructions
Two service levels are offered: Global and Tech Only. For Tech Only, laboratories should send both a circled hematoxylin & eosin (H&E) slide and a paraffin block; cut slides should include one H&E-stained slide (required) and four unstained slides sectioned at 4–5 microns. Cold pack shipping should be used, avoiding direct contact with the specimen. New York State clients must provide the date and time of collection.
Limitations
This is a targeted FISH assay; it does not detect genomic alterations beyond MET amplification or polysomy-related phenomena. Insufficient or decalcified tissue may compromise results; interpretation may be equivocal in cases of chromosome 7 polysomy. The assay does not capture other chromosomal abnormalities or mutations outside the MET locus.
New York Approved
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Formalin‑fixed paraffin block or unstained slides
Collection Instructions
Send paraffin block. For tech‑only, also send circled H&E slide plus four unstained slides (4–5 microns).